Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Public ClinicalTrials.gov record NCT04270760. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp\[a\]).
Study identification
- NCT ID
- NCT04270760
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 281 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 28, 2020 (Actual)
- Primary completion
- Dec 27, 2021 (Actual)
- Completion
- Nov 8, 2022 (Actual)
- Last update posted
- Mar 31, 2026
2020 – 2022
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Westside Medical Associates of Los Angeles | Beverly Hills | California | 90211 | — |
| Excel Medical Clinical Trials | Boca Raton | Florida | 33434 | — |
| Piedmont Healthcare | Atlanta | Georgia | 30309 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| Johns Hopkins | Baltimore | Maryland | 21287 | — |
| New York University | New York | New York | 10016 | — |
| Mount Sinai Hospital | New York | New York | 10029 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Crossroads Clinical Research Inc | Mooresville | North Carolina | 28117 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Protenium Clinical Research | Hurst | Texas | 76054 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04270760, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 31, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04270760 live on ClinicalTrials.gov.